• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    5/8/25 4:08:55 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    zyme-20250508
    0001937653false00019376532025-05-082025-05-08

      
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 8, 2025
     
    Zymeworks Inc.
    (Exact name of registrant as specified in its charter)
     
     





    Delaware
     001-41535 88-3099146
    (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)


    108 Patriot Drive, Suite A, Middletown, Delaware
     19709
    (Address of principal executive offices) (Zip Code)
    (302) 274-8744
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



     



    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
     





    Title of each class Trading
    Symbol(s)
     Name of each exchange
    on which registered
    Common Stock, $0.00001 par value per share
     
    ZYME

     
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company  ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     
     




    ITEM 2.02RESULTS OF OPERATIONS AND FINANCIAL CONDITION
    On May 8, 2025, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Form 8-K”).

    ITEM 7.01REGULATION FD DISCLOSURES
    The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (www.zymeworks.com), its investor relations website (ir.zymeworks.com), its news site (ir.zymeworks.com/press-releases), its publications site (zymeworks.com/publications) and its events and presentations site (ir.zymeworks.com/events-and-presentations). The Company uses these channels, as well as social media, including its X account (@ZymeworksInc) and LinkedIn account (www.linkedin.com/company/zymeworks), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.

    ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
    (d) Exhibits
    Exhibit No.  Description
    99.1  
    Press Release dated May 8, 2025.
    104Cover Page Interactive Data File (embedded as Inline XBRL document)

    The information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     

    ZYMEWORKS INC.
    (Registrant)
     







    Date: May 8, 2025
     

     By: /s/ Leone Patterson

     

     Name: Leone Patterson

     

     Title: Executive Vice President, Chief Business Officer and Chief Financial Officer

    Get the next $ZYME alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    11/1/2024$12.00Overweight → Equal Weight
    Wells Fargo
    3/21/2023$12.00Overweight
    Wells Fargo
    1/4/2023$10.00 → $8.00Neutral
    H.C. Wainwright
    12/20/2022$7.70 → $11.00Hold → Buy
    Jefferies
    11/1/2022$40.00 → $8.00Buy → Neutral
    H.C. Wainwright
    10/21/2022$8.00Outperform → Mkt Perform
    SVB Leerink
    More analyst ratings

    $ZYME
    SEC Filings

    See more
    • SEC Form 10-Q filed by Zymeworks Inc.

      10-Q - Zymeworks Inc. (0001937653) (Filer)

      5/8/25 4:11:33 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zymeworks Inc. (0001937653) (Filer)

      5/8/25 4:08:55 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.

      SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)

      5/7/25 11:43:19 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference call with management today at 4:30 p.m. Eastern Time (ET) VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to imp

      5/8/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

      Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the Americ

      4/25/25 1:00:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,497,322 worth of shares (127,415 units at $11.75) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/2/25 7:02:09 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,497,322 worth of shares (127,415 units at $11.75) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/2/25 7:02:09 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 9:00:57 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 4:27:20 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zymeworks Inc.

      SC 13G - Zymeworks Inc. (0001937653) (Subject)

      11/13/24 4:30:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zymeworks upgraded by Analyst with a new price target

      Analyst upgraded Zymeworks from Neutral to Overweight and set a new price target of $18.00

      12/16/24 6:40:30 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Zymeworks from Market Perform to Outperform and set a new price target of $25.00 from $10.00 previously

      11/7/24 6:47:25 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Zymeworks from Overweight to Equal Weight and set a new price target of $12.00

      11/1/24 7:40:43 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    See more
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

      VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two de

      2/18/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO

      Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r

      8/6/24 7:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Financials

    Live finance-specific insights

    See more
    • Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference call with management today at 4:30 p.m. Eastern Time (ET) VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to imp

      5/8/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. The event will be webcast live with dial-in details and webcast replay

      4/17/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAcceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC)Reported $324.2 million in cash resources as of December 31, 2024, which when combined with certain anticipated

      3/5/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care